Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity



Summary



GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity”. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals’ JR-031 (2014) in Japan and FCB Pharmicell’s Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.



Scope


- Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore
- In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers.
- Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem.
- Key drivers and restraints that have a significant impact on the market.
- Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost
- Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.



Reasons to buy


- Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
- Develop key strategic initiatives by studying the key strategies of top competitors
- Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety

Table Of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Stem Cell Therapy Market in Asia-Pacific to 2018 - Introduction 13
3 Stem Cell Therapy Market in Asia-Pacific to 2018 - Overview 14
3.1 Introduction 14
3.2 Market Characterization and Forecasts - Overview 15
3.2.1 Revenue Forecasts 15
3.2.2 Cost of Therapy 16
3.2.3 Allogeneic and Autologous Share 17
3.2.4 Stem Cell Therapy Patient Pool 18
3.3 Drivers and Barriers 19
3.3.1 Drivers 20
3.3.2 Barriers 20
4 Stem Cell Therapy Market in Asia-Pacific to 2018 - India 21
4.1 Introduction 21
4.2 Regulatory Landscape 21
4.3 Market Characterization and Forecasts - Overview 22
4.3.1 Revenue Forecasts 22
4.3.2 Cost of Therapy 23
4.3.3 Stem Cell Patient Pool 23
4.4 CABG Market Characterization and Forecasts 24
4.4.1 Introduction 24
4.4.2 Revenue Forecasts 24
4.4.3 Cost of Therapy 25
4.4.4 Stem Cell Patient Pool 26
4.5 Type 2 DM Market Characterization and Forecasts 27
4.5.1 Introduction 27
4.5.2 Revenue Forecasts 28
4.5.3 Cost of Therapy 29
4.5.4 Stem Cell Patient Pool 30
4.6 LSCT Market Characterization and Forecasts 31
4.6.1 Introduction 31
4.6.2 Revenue Forecasts 31
4.6.3 Cost of Therapy 32
4.6.4 Stem Cell Patient Pool 33
5 Stem Cell Therapy Market in Asia-Pacific to 2018 - China 34
5.1 Introduction 34
5.2 Regulatory Landscape 34
5.3 Market Characterization and Forecasts - Overview 35
5.3.1 Type 1 DM Market Characterization and Forecasts 35
6 Stem Cell Therapy Market in Asia-Pacific to 2018 - Japan 39
6.1 Introduction 39
6.2 Regulatory Landscape 39
6.3 Steroid Refractory aGvHD Market Characterization and Forecasts 41
6.3.1 Overview 41
6.3.2 Revenue Forecasts 42
6.3.3 Cost of Therapy 43
6.3.4 Stem Cell Patient Pool 44
7 Stem Cell Therapy Market in Asia-Pacific to 2018 - Singapore 45
7.1 Introduction 45
7.2 Regulatory Landscape 45
7.2.1 Ethical, Legal and Social Issues in Human Stem Cell Research, Reproductive and Therapeutic Cloning (June 2002) 46
7.2.2 Human Tissue Research (November 2002) 47
7.2.3 Research Involving Human Subjects (November 2004) 48
7.2.4 Genetic Testing and Genetic Research (November 2005) 49
7.2.5 Personal Information in Biomedical Research (May 2007) 50
7.2.6 Donation of Human Eggs for Research (November 2008) 50
7.2.7 Human-Animal Combinations in Stem Cell Research (September 2010) 50
8 Stem Cell Therapy Market in Asia-Pacific to 2018 - South Korea 51
8.1 Introduction 51
8.2 Regulatory Landscape 51
8.3 Market Characterization and Forecasts - Overview 53
8.3.1 Revenue Forecasts 53
8.3.2 Cost of Therapy 55
8.3.3 Stem Cell Patient Pool 56
8.4 Cupistem Market Characterization and Forecasts 57
8.4.1 Overview 57
8.4.2 Revenue Forecasts 58
8.4.3 Cost of Therapy 59
8.4.4 Stem Cell Patient Pool 60
8.5 HCG-AMI Market Characterization and Forecasts 61
8.5.1 Overview 61
8.5.2 Revenue Forecasts 62
8.5.3 Cost of Therapy 63
8.5.4 Stem Cell Patient Pool 64
8.6 Cartistem Market Characterization and Forecasts 65
8.6.1 Overview 65
8.6.2 Revenue Forecasts 66
8.6.3 Cost of Therapy 67
8.6.4 Stem Cell Patient Pool 68
8.7 CCG Market Characterization and Forecasts 69
8.7.1 Overview 69
8.7.2 Revenue Forecasts 69
8.7.3 Cost of Therapy 70
8.7.4 Stem Cell Patient Pool 71
9 Stem Cell Therapy Market in Asia-Pacific to 2018 - Pipeline Analysis 72
9.1 Pipeline Analysis by Phase 72
9.2 Pipeline Analysis by Sponsors/Collaborators 73
9.3 Pipeline Analysis by Country 74
9.3.1 India Stem Cell RandD Pipeline 75
9.3.2 China Stem Cell RandD Pipeline 77
9.3.3 Japan Stem Cell RandD Pipeline 81
9.3.4 Singapore Stem Cell RandD Pipeline 85
9.3.5 South Korea Stem Cell RandD Pipeline 86
9.3.6 Product Profiles of Promising Molecules 88
9.3.7 Product Profiles of Marketed Products 89
10 Stem Cell Therapy Market in Asia-Pacific to 2018 - Competitive Landscape 91
10.1 Stempeutics Research 91
10.1.1 Overview 91
10.1.2 Product Pipeline 92
10.2 Reliance Life Sciences 93
10.2.1 Overview 93
10.2.2 Product Pipeline 93
10.3 International Stem Cell Services 94
10.3.1 Overview 94
10.3.2 Product Pipeline 94
10.4 Shenzhen Beike Biotechnology 95
10.4.1 Overview 95
10.4.2 Product Pipeline 95
10.5 JCR Pharmaceuticals 96
10.5.1 Overview 96
10.5.2 Product Pipeline 96
10.6 ES Cells International (Subsidiary of BioTime, Inc) 97
10.6.1 Overview 97
10.6.2 Product Pipeline 97
10.7 Stem Cell Technologies i 98
10.7.1 Overview 98
10.7.2 Product Pipeline 98
10.8 Pharmicell 99
10.8.1 Overview 99
10.8.2 Product Pipeline 99
10.9 Medipost 100
10.9.1 Overview 100
10.9.2 Product Pipeline 100
11 Stem Cell Therapy Market in Asia-Pacific to 2018 - Strategic Consolidations 101
11.1 Overview 101
11.2 MandA Deals 102
11.2.1 RNL BIO Acquired 10% Stake in Celltex Therapeutics for $10m - October 28, 2011 102
11.2.2 BioTime Acquired ES Cell International - May 3, 2010 102
11.2.3 BCCL Acquires Stake in Life Cell - May 1, 2007 102
11.3 Licensing Deals 102
11.3.1 RNL BIO Forms Joint Venture to Develop Stem Cell Therapy - September 29, 2011 102
11.3.2 Kiadis Pharma Enters into Licensing Agreement with Hospira for ATIR - January 4, 2011 102
11.3.3 Cipla Enters into Co-Marketing Agreement with Stempeutics - April 27, 2010 102
11.3.4 Teijin Enters into Licensing Agreement with SanBio - March 2, 2010 102
11.3.5 Cleveland BioLabs Enters into Licensing Agreement with Zhejiang Hisun Pharma - September 9, 2009 103
11.3.6 Merck Signs a Licensing Agreement with Japan Tobacco - September 25, 2008 103
11.3.7 ES Cell Enters into Licensing Agreement with ITI Life Sciences - January 31, 2007 103
11.4 Co-Development Deals 103
11.4.1 JCR Pharma Enters into Co-Development Agreement with MediPal - September 13, 2011 103
11.4.2 Athersys Enters into Co-Development Agreement with Pfizer - December 21, 2009 103
11.4.3 Genzyme Enters into Agreement with Osiris Therapeutics - November 4, 2008 104
11.4.4 JCR Pharma Enters into Co-Development Agreement with Mochida Pharma - December 21, 2007 104
12 Stem Cell Therapy Market in Asia-Pacific to 2018 - Appendix 105
12.1 Market Definitions 105
12.2 Abbreviations 105
12.3 Bibliography 107
12.4 Research Methodology 108
12.4.1 Coverage 108
12.4.2 Secondary Research 108
12.4.3 Primary Research 109
12.5 Therapeutic Landscape 109
12.5.2 Market Size by Geography 111
12.6 Geographical Landscape 112
12.7 Pipeline Analysis 112
12.8 Competitive Landscape 112
12.8.1 Expert Panel Validation 112
12.9 Contact Us 112
12.10 Disclaimer 112

List of Tables
1.1 List of Tables
Table 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018 15
Table 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts (‘000), 2012-2018 18
Table 3: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018 22
Table 4: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts (‘000), 2012-2018 23
Table 5: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($’000), 2012-2018 24
Table 6: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018 25
Table 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018 26
Table 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018 28
Table 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018 29
Table 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts (‘000), 2012-2018 30
Table 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($’000), 2012-2018 31
Table 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018 32
Table 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018 33
Table 14: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018 36
Table 15: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018 37
Table 16: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts (‘000), 2012-2018 38
Table 17: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018 42
Table 18: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018 43
Table 19: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018 44
Table 20: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018 53
Table 21: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018 56
Table 22: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018 58
Table 23: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018 59
Table 24: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018 60
Table 25: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018 62
Table 26: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018 63
Table 27: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts, 2012-2018 64
Table 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018 66
Table 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018 67
Table 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018 68
Table 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018 69
Table 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018 70
Table 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018 71
Table 34: Stem Cell Therapy Market in Asia-Pacific to 2018, RandD Pipeline Analysis by Phase, 2012 72
Table 35: Stem Cell Therapy Market in Asia-Pacific to 2018, RandD Pipeline Analysis by Sponsors/Collaborators, 2012 73
Table 36: Stem Cell Therapy Market in Asia-Pacific to 2018, RandD Pipeline Analysis by Country, 2012 74
Table 37: Stem Cell Therapy Market in Asia-Pacific to 2018, India, RandD Pipeline Analysis by Phase, 2012 75
Table 38: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II/III Pipeline Analysis, 2012 76
Table 39: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II Pipeline Analysis, 2012 76
Table 40: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase I/II Pipeline Analysis, 2012 76
Table 41: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Unknown Phase, 2012 76
Table 42: Stem Cell Therapy Market in Asia-Pacific to 2018, China, RandD Pipeline Analysis by Phase, 2012 77
Table 43: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Post-Market Pipeline Analysis, 2012 78
Table 44: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase II Pipeline Analysis, 2012 78
Table 45: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I/II Pipeline Analysis, 2012 79
Table 46: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I Pipeline Analysis, 2012 79
Table 47: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Clinical Pre-Test Pipeline Analysis, 2012 80
Table 48: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Unknown Phase, 2012 80
Table 49: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, RandD Pipeline Analysis by Phase, 2012 81
Table 50: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase III Stage Molecules Pipeline Analysis, 2012 82
Table 51: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II/III Stage Molecules Pipeline Analysis, 2012 82
Table 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II Stage Molecules Pipeline Analysis, 2012 83
Table 53: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I/II Stage Molecules Pipeline Analysis, 2012 84
Table 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I Stage Molecules Pipeline Analysis, 2012 84
Table 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Singapore, Phase I/II Stage Molecules Pipeline Analysis, 2012 85
Table 56: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, RandD Pipeline Analysis by Phase, 2012 86
Table 57: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase III Molecules Pipeline Analysis, 2012 87
Table 58: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II/III Molecules Pipeline Analysis, 2012 87
Table 59: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II Molecules Pipeline Analysis, 2012 87
Table 60: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I/II Molecules Pipeline Analysis, 2012 87
Table 61: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I Molecules Pipeline Analysis, 2012 88
Table 62: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Unknown Phase, 2012 88
Table 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, RandD Pipeline, 2012 92
Table 64: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, RandD Pipeline, 2012 93
Table 65: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services Limited, RandD Pipeline, 2012 94
Table 66: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology RandD Pipeline, 2012 95
Table 67: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Co. Ltd, RandD Pipeline, 2012 96
Table 68: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell, RandD Pipeline, 2012 99
Table 69: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, RandD Pipeline, 2012 100
Table 70: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview, 2007-2012 101

List of Figures
1.2 List of Figures
Figure 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Overview, 2012 14
Figure 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018 15
Figure 3: Stem Cell Therapy Market in Asia-Pacific to 2018, Cost of Therapy Overview ($), 2012 16
Figure 4: Stem Cell Therapy Market in Asia-Pacific to 2018, Allogeneic vs. Autologous (%), 2012 17
Figure 5: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts (‘000), 2012-2018 18
Figure 6: Stem Cell Therapy Market in Asia-Pacific to 2018, Drivers and Barriers, 2012 19
Figure 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018 22
Figure 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Cost of Therapy Overview ($), 2012 23
Figure 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts (‘000), 2012-2018 23
Figure 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($’000), 2012-2018 24
Figure 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018 25
Figure 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018 26
Figure 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018 28
Figure 14: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018 29
Figure 15: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts (‘000), 2012-2018 30
Figure 16: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($’000), 2012-2018 31
Figure 17: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018 32
Figure 18: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018 33
Figure 19: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Regulatory Framework Timeline, 1998-2009 34
Figure 20: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018 36
Figure 21: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018 37
Figure 22: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts (‘000), 2012-2018 38
Figure 23: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, MHLW Stem Cell Guidelines, 2010 39
Figure 24: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, JR-031 Overview, 2012 41
Figure 25: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018 42
Figure 26: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018 43
Figure 27: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018 44
Figure 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Stem Cell Therapeutics Approval Process, 2011 51
Figure 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Biopharmaceutical Implementation Strategies, 2011 52
Figure 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018 53
Figure 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Autologous and Allogeneic Share (%), 2012 54
Figure 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Marketed Products Share (%), 2012 and 2018 54
Figure 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cost of Therapy ($), Overview, 2012 55
Figure 34: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018 56
Figure 35: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018 58
Figure 36: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018 59
Figure 37: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018 60
Figure 38: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018 62
Figure 39: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018 63
Figure 40: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts (Absolute), 2012-2018 64
Figure 41: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018 66
Figure 42: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018 67
Figure 43: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018 68
Figure 44: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018 69
Figure 45: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018 70
Figure 46: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018 71
Figure 47: Stem Cell Therapy Market in Asia-Pacific to 2018, RandD Pipeline Analysis by Phase (%), 2012 72
Figure 48: Stem Cell Therapy Market in Asia-Pacific to 2018, RandD Pipeline Analysis by Sponsors/Collaborators (%), 2012 73
Figure 49: Stem Cell Therapy Market in Asia-Pacific to 2018, RandD Pipeline Analysis by Country (%), 2012 74
Figure 50: Stem Cell Therapy Market in Asia-Pacific to 2018, India, RandD Pipeline Analysis by Phase (%), 2012 75
Figure 51: Stem Cell Therapy Market in Asia-Pacific to 2018, China, RandD Pipeline Analysis by Phase (%), 2012 77
Figure 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, RandD Pipeline Analysis by Phase (%), 2012 81
Figure 53: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, RandD Pipeline Analysis by Phase (%), 2012 86
Figure 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, Overview, 2012 91
Figure 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, Overview, 2012 93
Figure 56: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services, Overview, 2012 94
Figure 57: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology Overview, 2012 95
Figure 58: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Overview, 2012 96
Figure 59: Stem Cell Therapy Market in Asia-Pacific to 2018, ES Cells International, Overview, 2012 97
Figure 60: Stem Cell Therapy Market in Asia-Pacific to 2018, Stem Cell Technologies i, Overview, 2012 98
Figure 61: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell Overview, 2012 99
Figure 62: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, Overview, 2012 100
Figure 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview (%), 2007-2012 101
Figure 64: GBI Research Market Forecasting Model 111

Companies Mentioned
Stempeutics Research
Reliance Life Sciences
International Stem Cell Services
Shenzhen Beike Biotechnology
JCR Pharmaceuticals
ES Cells International (Subsidiary of BioTime, Inc)
Stem Cell Technologies i
Pharmicell
Medipost

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Tissue Engineering and Regeneration: Technologies and Global Markets

Tissue Engineering and Regeneration: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • August 2014
  • by BCC Research

This BCC Research report presents an in-depth analysis of the global tissue engineering and regeneration market by technologies, materials, applications segments and regional markets. It includes comprehensive ...

Regenerative Medicine Market (Bone and Joint) (By Technology - Stem Cell Therapy, Biomaterial and Tissue Engineering; By Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products and Others) - Global Industry

Regenerative Medicine Market (Bone and Joint) (By Technology - Stem Cell Therapy, Biomaterial and Tissue Engineering; By Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products and Others) - Global Industry

  • $ 4 795
  • Industry report
  • July 2014
  • by Transparency Market Research

U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage, congenital ...

Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019

Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019

  • $ 4 650
  • Industry report
  • September 2014
  • by MarketsandMarkets

Over the years, the cell line development market has witnessed various technological advancements in order to cater to the growing demand for stable and high-yielding cell lines. These advancements have ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.